Clinical pharmacological aspects of dihydroergotamine timed release: activity on monoamine venospasm.
Using the computerized venotest, it is possible to evaluate both the venospastic activity of the vasoactive monoamines (NA,5-HT, DA) and the effects of the relative agonistic and antagonistic drugs. The ergot-derivatives are 5-HT and NA agonists at low doses, and are 5-HT antagonists at high doses. Dihydroergotamine timed release (DHE-TR) administered orally is capable at 12 hours following the last administration of producing a significant increase of 5-HT and NA venospasm. It is hypothesized that 12 hours after the last administration of DHE-TR, hematic concentrations, corresponding to clinical and therapeutic levels, capable of potentiating the monoamine venospasm still exists.
D000328:Adult; D003692:Delayed-Action Preparations; D004087:Dihydroergotamine / Q000494:pharmacology*; D005260:Female; D006225:Hand / Q000098:blood supply; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D009638:Norepinephrine / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013035:Spasm / Q000188:drug therapy*; D014690:Venous Pressure / Q000187:drug effects*
D003692:Delayed-Action Preparations; D012701:Serotonin; D004087:Dihydroergotamine; D009638:Norepinephrine